공고 • Aug 05
Pinnacle Food Group Limited Announces Appointment of Martin Ngai Lam Cheung as Independent Director, Effective August 1, 2026 Pinnacle Food Group Limited announced the appointment of Mr. Martin Ngai Lam Cheung as an independent director of the Company, effective August 1, 2026. Mr. Cheung, 57, has extensive public company board, audit committee, corporate finance, accounting, reporting and compliance experience. He currently serves as an independent non-executive director and audit committee chair of China Development Bank International Investment Co. Ltd., New Provenance Everlasting Company Limited and Boyaa Interactive International Company Limited. Mr. Cheung previously served in director and audit committee chair roles with several Hong Kong-listed and Nasdaq-listed companies, including ATV Company Limited, Ninetowns Technology Internet Group, China Environmental Resources Group, Hong Long Holdings Ltd, Mascotte Holding Ltd, Silk Road Logistics Holdings Ltd. and China Huishan Dairy Holdings. From 2014 to 2022, Mr. Cheung served as Vice President and Chief Financial Officer of China Zenix Auto International Limited, where his responsibilities included public company listing compliance, corporate governance, financial reporting and investor relations. Earlier in his career, Mr. Cheung held senior corporate finance, capital markets and audit positions with Norstar Founders Group Limited, Grant Thornton Corporate Finance Limited, Japan Asia Securities Limited, Daiwa Securities SMBC Hong Kong Limited and Deloitte Touche Tohmatsu. Mr. Cheung holds a Master of Science in Investment Management from The Hong Kong University of Science and Technology, a Master of Accounting from Curtin University and a Bachelor of Social Sciences from The University of Hong Kong. He is a member of the American Institute of Certified Public Accountants and a CPA Australia member. The Board of Directors of the Company determined that Mr. Cheung is independent under Nasdaq Listing Rule 5605(a)(2), satisfies the additional independence requirements of Rule 10A-3 under the Securities Exchange Act of 1934, as amended, and meets the Company's corporate governance requirements. The Board further determined that Mr. Cheung qualifies as an "audit committee financial expert" within the meaning of the applicable rules of the U.S. Securities and Exchange Commission. New Risk • Aug 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Revenue is less than US$5m (US$3.4m revenue). Market cap is less than US$100m (US$29.2m market cap). Reported Earnings • May 05
Full year 2025 earnings released: US$0.17 loss per share (vs US$0.03 profit in FY 2024) Full year 2025 results: US$0.17 loss per share (down from US$0.03 profit in FY 2024). Revenue: US$3.41m (up 3.7% from FY 2024). Net loss: US$1.90m (down US$2.19m from profit in FY 2024). 공고 • Apr 17
Pinnacle Food Group Limited Announces Breakthrough in Recombinant Human Lactoferrin Production Using Cost-Effective Methanol-Free Fermentation Method Pinnacle Food Group Limited announced a significant technical milestone in its precision fermentation R&D pipeline achieved at its laboratory in Hong Kong. The research team created the first generation of a recombinant yeast strain to produce human lactoferrin (rhLF) using a patented methanol-free Pichia fermentation method, accessed through the Company's research collaboration with Bioboost. Unlike traditional fermentation which relies on methanol-a highly flammable, toxic solvent that requires massive capital expenditure (CapEx) for explosion-proof facilities-this advanced platform eliminates methanol to fundamentally mitigate severe fire hazards and substantially reduce operational costs. It also ensures zero toxic residue, a critical advantage for high-purity infant nutrition and pharmaceutical applications. While the rhLF strain continues to advance, the underlying methanol-free technology platform has already been successfully validated with other protein targets at pilot scale, demonstrating its robust readiness for commercial manufacturing. Human lactoferrin (rhLF) is a high-value functional protein widely sourced by manufacturers in infant nutrition, dietary supplements, and pharmaceutical applications. It is a bioengineered, iron-binding glycoprotein structurally similar to natural human milk protein. Reported Earnings • Nov 24
First half 2025 earnings released: US$0.076 loss per share (vs US$0.032 loss in 1H 2024) First half 2025 results: US$0.076 loss per share (further deteriorated from US$0.032 loss in 1H 2024). Revenue: US$926.6k (up 29% from 1H 2024). Net loss: US$808.7k (loss widened 169% from 1H 2024). 
